Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 4 25 W DEXTROSE 25 IN PLASTIC CONTAINER versus AMINOSYN 5.
AMINOSYN 4.25% W/ DEXTROSE 25% IN PLASTIC CONTAINER vs AMINOSYN 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn 4.25% w/ Dextrose 25% provides amino acids for protein synthesis and dextrose as a caloric source, supporting nitrogen balance and energy requirements in parenteral nutrition.
Aminosyn 5% provides essential and nonessential amino acids for protein synthesis, maintaining nitrogen balance, and supporting tissue repair in patients unable to tolerate oral intake.
Adults: 1-3 L/day intravenously through central line. Infusion rate initially 50-100 mL/hour, titrate to achieve protein and calorie requirements.
Intravenous infusion; 500 mL of 5% solution (25 g protein equivalent) per day, typically at a rate not exceeding 100 mL/hour. Dosage individualized based on protein requirements and metabolic status.
None Documented
None Documented
Amino acids: 10-30 min (rapid distribution). Dextrose: glucose half-life ~1.5-2 h in euglycemia; prolonged in renal impairment. Clinically, continuous infusion maintains steady state without significant accumulation.
Not applicable as a drug; amino acids have rapid turnover with half-lives varying from minutes to hours depending on the individual amino acid.
Amino acids are metabolized; nitrogen waste is excreted renally as urea. Dextrose is metabolized to CO2 and water. Renal excretion accounts for >95% of nitrogen elimination. Minimal biliary/fecal elimination.
Amino acids are metabolized; nitrogen is excreted renally as urea (80-90%) and in feces (5-10%).
Category C
Category C
Amino Acid Solution
Amino Acid Solution